The in vitro identification and quantification of volatile biomarkers released by cystic fibrosis pathogens

There is interest in the development of exhaled breath tests for the detection of lower airway infection in children with cystic fibrosis. The first stage of this process is the identification of volatile organic compounds (VOCs) released into the gas phase by CF pathogens that can be used as breath test biomarkers. Selected ion flow tube mass spectrometry (SIFT-MS) is ideally suited to these in vitro studies as it allows simultaneous quantification of multiple VOCs in real time. We review a decade of in vitro experiments using SIFT-MS to analyse the VOCs released by respiratory pathogens. This includes identification and quantification of VOCs and the investigation of the in vitro factors that affect their production. We also report on how our culture methodology has been refined over the years to better account for variations in bacterial mass. Finally, we discuss how these in vitro findings have been translated into clinical trials and assess possible future applications.

[1]  David Smith,et al.  Quantification by SIFT-MS of volatile compounds emitted by Aspergillus fumigatus cultures and in co-culture with Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae , 2014 .

[2]  David Smith,et al.  Quantification by SIFT-MS of volatile compounds emitted by in vitro cultures of S. aureus, S. pneumoniae and H. influenzae isolated from patients with respiratory diseases , 2014 .

[3]  P. Španěl,et al.  Hydrogen cyanide, a volatile biomarker of Pseudomonas aeruginosa infection , 2013, Journal of breath research.

[4]  A. Cheepsattayakorn,et al.  Breath Tests in Respiratory and Critical Care Medicine: From Research to Practice in Current Perspectives , 2013, BioMed research international.

[5]  David Smith,et al.  Is Hydrogen Cyanide a Marker of Burkholderia cepacia Complex? , 2013, Journal of Clinical Microbiology.

[6]  David Smith,et al.  Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without Pseudomonas aeruginosa infection , 2013, Journal of breath research.

[7]  M. Quintel,et al.  Detection and validation of volatile metabolic patterns over different strains of two human pathogenic bacteria during their growth in a complex medium using multi-capillary column-ion mobility spectrometry (MCC-IMS) , 2013, Applied Microbiology and Biotechnology.

[8]  David Smith,et al.  Quantification of hydrogen cyanide and 2-aminoacetophenone in the headspace of Pseudomonas aeruginos , 2012 .

[9]  V. Shestivska,et al.  Variability in the concentrations of volatile metabolites emitted by genotypically different strains of Pseudomonas aeruginosa , 2012, Journal of applied microbiology.

[10]  S. Sekaran,et al.  Detection of Quorum Sensing Signal Molecules and Identification of an Autoinducer Synthase Gene among Biofilm Forming Clinical Isolates of Acinetobacter spp. , 2012, PloS one.

[11]  Anton Amann,et al.  Molecular analysis of volatile metabolites released specifically by staphylococcus aureus and pseudomonas aeruginosa , 2012, BMC Microbiology.

[12]  V. Shestivska,et al.  Quantification of methyl thiocyanate in the headspace of Pseudomonas aeruginosa cultures and in the breath of cystic fibrosis patients by selected ion flow tube mass spectrometry. , 2011, Rapid communications in mass spectrometry : RCM.

[13]  L. Halonen,et al.  Background levels and diurnal variations of hydrogen cyanide in breath and emitted from skin , 2011, Journal of breath research.

[14]  J. Pearson,et al.  Potential sources of 2-aminoacetophenone to confound the Pseudomonas aeruginosa breath test, including analysis of a food challenge study , 2011, Journal of breath research.

[15]  David Smith,et al.  Progress in SIFT-MS: breath analysis and other applications. , 2011, Mass spectrometry reviews.

[16]  K. Webb,et al.  Variation in hydrogen cyanide production between different strains of Pseudomonas aeruginosa , 2011, European Respiratory Journal.

[17]  R. Laing,et al.  2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung , 2010, BMC pulmonary medicine.

[18]  P. Sly,et al.  Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosis , 2010, European Respiratory Journal.

[19]  N. Høiby,et al.  Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients , 2009, Pediatric pulmonology.

[20]  J. Davies,et al.  Bugs, biofilms, and resistance in cystic fibrosis. , 2009, Respiratory care.

[21]  David Smith,et al.  Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis , 2009, Pediatric pulmonology.

[22]  Tianshu Wang,et al.  Analysis of breath, exhaled via the mouth and nose, and the air in the oral cavity , 2008, Journal of breath research.

[23]  B. Ryall,et al.  Bacteria of the Burkholderia cepacia complex are cyanogenic under biofilm and colonial growth conditions , 2008, BMC Microbiology.

[24]  P. Španěl,et al.  The challenge of breath analysis for clinical diagnosis and therapeutic monitoring. , 2007, The Analyst.

[25]  David Smith,et al.  A general method for the calculation of absolute trace gas concentrations in air and breath from selected ion flow tube mass spectrometry data , 2006 .

[26]  J. Hupp,et al.  Mucin–Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance , 2006, Molecular microbiology.

[27]  M. Dierich,et al.  Diagnosis of Bacteria In Vitro by Mass Spectrometric Fingerprinting:A Pilot Study , 2005, Current Microbiology.

[28]  David Smith,et al.  Detection of volatile compounds emitted by Pseudomonas aeruginosa using selected ion flow tube mass spectrometry , 2005, Pediatric pulmonology.

[29]  D. Hassett,et al.  The Transcriptional Regulator AlgR Controls Cyanide Production in Pseudomonas aeruginosa , 2004, Journal of bacteriology.

[30]  E. Drenkard.  Antimicrobial resistance of Pseudomonas aeruginosa biofilms. , 2003, Microbes and infection.

[31]  N. Høiby,et al.  Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment , 1991, The Lancet.

[32]  B. Ryall,et al.  Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa. , 2007, Advances in microbial physiology.